All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-06-05T13:27:32.000Z

ASCO 2019 | Highlights of the randomized phase III COLUMBA study

Bookmark this article

Maria-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, talks to the MM Hub at ASCO 2019 about the phase III COLUMBA results. The study reports that subcutaneous administration of daratumumab (dara-SC) is non-inferior to intravenous administration (dara-IV). In a satisfaction questionnaire, patients reported a more favorable experience with dara-SC making it an attractive and viable option, both in terms of efficacy, and patient quality-of-life. Professor Mateos added that she believes daratumumab will be mainly administered subcutaneously, in the near future.

Maria-Victoria Mateos kindly gave her interview in Spanish, with the title: Resultados del ensayo randomizado fase III COLUMBA.

Highlights of the randomized phase III COLUMBA study

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox